Management of antiplatelet therapy resistance in cardiac surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 147, Issue 3, 2014, Pages 855-862

  Gasparovic, Hrvoje ^a   Petricevic, Mate ^a   Biocina, Bojan ^a  

^a KBC Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; TICAGRELOR;

BLOOD CLOTTING PARAMETERS; HEART SURGERY; HUMAN; PLATELET REACTIVITY; PRIORITY JOURNAL; REVIEW; THERAPY RESISTANCE; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

CARDIAC SURGICAL PROCEDURES; CORONARY THROMBOSIS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84894025083     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2013.10.008     Document Type: Editorial

References (66)

1. N. Zimmermann, E. Gams, and T. Hohlfeld Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent Eur J Cardiothorac Surg 34 2008 93 108
2. Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration BMJ 308 1994 159 168
3. M.G. Bourassa, L.D. Fisher, L. Campeau, M.J. Gillespie, M. McConney, and J. Lesperance Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences Circulation 72 1985 V71 V78
4. J.H. Chesebro, V. Fuster, L.R. Elveback, I.P. Clements, H.C. Smith, and D.R. Holmes Jr. et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations N Engl J Med 310 1984 209 214
5. V.A. Mannacio, L. Di Tommaso, A. Antignan, V. De Amicis, and C. Vosa Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study Heart 98 2012 1710 1715
6. J.H. Alexander, G. Hafley, R.A. Harrington, E.D. Peterson, T.B. Ferguson Jr., and T.J. Lorenz et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial JAMA 294 2005 2446 2454
7. J.G. Motwani, and E.J. Topol Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention Circulation 97 1998 916 931
8. A.A. Cameron, K.B. Davis, and W.J. Rogers Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study J Am Coll Cardiol 26 1995 895 899
9. P.W. Serruys, M.C. Morice, A.P. Kappetein, A. Colombo, D.R. Holmes, and M.J. Mack et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 2009 961 972
10. J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, and U. Lockowandt et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery Eur J Cardiothorac Surg 34 2008 73 92
11. R.L. Lorenz, C.V. Schacky, M. Weber, W. Meister, J. Kotzur, and B. Reichardt et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation Lancet 1 1984 1261 1264
12. G.V. Sharma, S.F. Khuri, M. Josa, E.D. Folland, and A.F. Parisi The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency Circulation 68 1983 II218 II221
13. T.J. Gluckman, R.C. McLean, S.P. Schulman, T.S. Kickler, E.P. Shapiro, and J.V. Conte et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery J Am Coll Cardiol 57 2011 1069 1077
14. N. Zimmermann, P. Kienzle, A.A. Weber, J. Winter, E. Gams, and K. Schror et al. Aspirin resistance after coronary artery bypass grafting J Thorac Cardiovasc Surg 121 2001 982 984
15. P.A. Gurbel, and U.S. Tantry Drug insight: clopidogrel nonresponsiveness Nat Clin Pract Cardiovasc Med 3 2006 387 395
16. S.G. Ahn, J. Yoon, J. Kim, Y. Uh, K.M. Kim, and J.H. Lee et al. Genotype- and phenotype-directed personalization of antiplatelet treatment in patients with non-ST elevation acute coronary syndromes undergoing coronary stenting Korean Circ J 43 2013 541 549
17. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 2003 53 59
18. W.C. Lau, L.A. Waskell, P.B. Watkins, C.J. Neer, K. Horowitz, and A.S. Hopp et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 2003 32 37
19. V.L. Serebruany, A.I. Malinin, K.P. Callahan, P.A. Gurbel, and S.R. Steinhubl Statins do not affect platelet inhibition with clopidogrel during coronary stenting Atherosclerosis 159 2001 239 241
20. J. Saw, S.R. Steinhubl, P.B. Berger, D.J. Kereiakes, V.L. Serebruany, and D. Brennan et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 2003 921 924
21. S.P. Dunn, S.R. Steinhubl, D. Bauer, R.J. Charnigo, P.B. Berger, and E.J. Topol Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials J Am Heart Assoc 2 2013 e004564
22. M.L. O'Donoghue, E. Braunwald, E.M. Antman, S.A. Murphy, E.R. Bates, and Y. Rozenman et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
23. M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D.A. Palisaitis, and J.G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 2007 1702 1708
24. M. Petricevic, B. Biocina, S. Konosic, T. Kopjar, N. Kunac, and H. Gasparovic Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy Heart Vessels 28 2013 57 65
25. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655
26. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Beinart, and I. Goldenberg et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
27. R. Marcucci, A.M. Gori, R. Paniccia, B. Giusti, S. Valente, and C. Giglioli et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
28. N. Sambu, T. Warner, and N. Curzen Clopidogrel withdrawal: is there a "rebound" phenomenon? Thromb Haemost 105 2011 211 220
29. E. Mahla, T.A. Suarez, K.P. Bliden, P. Rehak, H. Metzler, and A.J. Sequeira et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 5 2012 261 269
30. U. Di Dedda, M. Ranucci, E. Baryshnikova, and S. Castelvecchio Thienopyridines resistance and recovery of platelet function after discontinuation of thienopyridines in cardiac surgery patients Eur J Cardiothorac Surg 2013 [Epub ahead of print]
31. H. Gasparovic, M. Petricevic, T. Kopjar, Z. Djuric, L. Svetina, and B. Biocina Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639] Trials 13 2012 148
32. S. Rafiq, P.I. Johansson, M. Zacho, T. Stissing, K. Kofoed, and N.B. Lilleor et al. Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial Trials 13 2012 48
33. P.A. Gurbel, and K.P. Bliden Durability of platelet inhibition by clopidogrel Am J Cardiol 91 2003 1123 1125
34. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
35. J. Golanski, S. Chlopicki, R. Golanski, P. Gresner, A. Iwaszkiewicz, and C. Watala Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy Ther Drug Monit 27 2005 484 490
36. N. Zimmermann, M. Kurt, J. Winter, E. Gams, F. Wenzel, and T. Hohlfeld Detection and duration of aspirin resistance after coronary artery bypass grafting J Thorac Cardiovasc Surg 135 2008 947 948
37. A. Abaci, Y. Yilmaz, M. Caliskan, F. Bayram, M. Cetin, and A. Unal et al. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes Thromb Res 116 2005 465 470
38. H. Neubauer, S. Lask, A. Engelhardt, and A. Mugge How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification Thromb Haemost 99 2008 357 362
39. C. Stellbaum, Y. Ayral, A. Morguet, H.P. Schultheiss, and U. Rauch Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry Cardiovasc Revasc Med 13 2012 159 166
40. H. Neubauer, A.F. Kaiser, H.G. Endres, J.C. Kruger, A. Engelhardt, and S. Lask et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy BMC Med 9 2011 3
41. T. Furuno, F. Yamasaki, T. Yokoyama, K. Sato, T. Sato, and Y. Doi et al. Effects of various doses of aspirin on platelet activity and endothelial function Heart Vessels 26 2011 267 273
42. V. Chan, A. Kulik, M.E. Bourke, L. Ressler, T.G. Mesana, and M. Ruel Clopidogrel is safe early after on- and off-pump coronary artery bypass surgery J Card Surg 22 2007 493 497
43. M. Petricevic, B. Biocina, D. Milicic, S. Konosic, V. Ivancan, and M. Milosevic et al. Bleeding risk assessment using multiple electrode aggregometry in patients following coronary artery bypass surgery J Thromb Thrombolysis 35 2013 31 40
44. O. Yousuf, and D.L. Bhatt The evolution of antiplatelet therapy in cardiovascular disease Nat Rev Cardiol 8 2011 547 559
45. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
46. P.K. Smith, L.T. Goodnough, J.H. Levy, R.S. Poston, M.A. Short, and G.J. Weerakkody et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis J Am Coll Cardiol 60 2012 388 396
47. F.W. Mohr, M.C. Morice, A.P. Kappetein, T.E. Feldman, E. Stahle, and A. Colombo et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial Lancet 381 2013 629 638
48. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
49. P.A. Gurbel, K.P. Bliden, K. Butler, M.J. Antonino, C. Wei, and R. Teng et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
50. D.L. Bhatt, G.W. Stone, K.W. Mahaffey, C.M. Gibson, P.G. Steg, and C.W. Hamm et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
51. L. Souckova, R. Opatrilova, P. Suk, I. Cundrle Jr., M. Pavlik, and V. Zvonicek et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR) Eur J Clin Pharmacol 69 2013 309 317
52. D.J. Angiolillo, M.S. Firstenberg, M.J. Price, P.E. Tummala, M. Hutyra, and I.J. Welsby et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial JAMA 307 2012 265 274
53. D.A. Morrow, E. Braunwald, M.P. Bonaca, S.F. Ameriso, A.J. Dalby, and M.P. Fish et al. Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
54. W.C. Lau, P.A. Gurbel, P.B. Watkins, C.J. Neer, A.S. Hopp, and D.G. Carville et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
55. V.A. Ferraris, J.R. Brown, G.J. Despotis, J.W. Hammon, T.B. Reece, and S.P. Saha et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines Ann Thorac Surg 91 2011 944 982
56. M. Ranucci, E. Baryshnikova, G. Soro, A. Ballotta, D. De Benedetti, and D. Conti Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines Ann Thorac Surg 91 2011 123 129
57. N. Sambu, A. Radhakrishnan, H. Dent, A.L. Calver, S. Corbett, and H. Gray et al. Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry Heart 98 2012 706 711
58. S. Preisman, A. Kogan, K. Itzkovsky, G. Leikin, and E. Raanani Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery Eur J Cardiothorac Surg 37 2010 1367 1374
59. J. Kempfert, K. Anger, A. Rastan, S. Krabbes, S. Lehmann, and J. Garbade et al. Postoperative development of aspirin resistance following coronary artery bypass Eur J Clin Invest 39 2009 769 774
60. F. Bednar, P. Osmancik, T. Vanek, H. Mocikova, M. Jares, and Z. Straka et al. Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET) J Thorac Cardiovasc Surg 136 2008 1054 1060
61. R. Poston, J. Gu, J. Manchio, A. Lee, J. Brown, and J. Gammie et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting Eur J Cardiothorac Surg 27 2005 584 591
62. O. Toth, A. Calatzis, S. Penz, H. Losonczy, and W. Siess Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood Thromb Haemost 96 2006 781 788
63. M. Petricevic, B. Biocina, S. Konosic, T. Kopjar, M. Milosevic, and H. Gasparovic Definition of acetylsalicylic acid resistance using multiple electrode aggregometry in patients following coronary artery bypass grafting T.H.S. Forum, 21st World Congress World Society of Cardio-Thoracic Surgeons Vol 14 2011 Abstract Book Berlin, Germany 70 71
64. B. Skoric, D. Milicic, D. Lovric, I. Gornik, K.N. Skoric, and J. Sertic Initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction is related to platelet response to aspirin Int J Cardiol 140 2010 356 358
65. C. Jambor, C.F. Weber, K. Gerhardt, W. Dietrich, M. Spannagl, and B. Heindl et al. Whole blood multiple electrode aggregometry is a reliable point-of-care test of aspirin-induced platelet dysfunction Anesth Analg 109 2009 25 31
66. P.A. Gurbel, K.P. Bliden, I.A. Navickas, E. Mahla, J. Dichiara, and T.A. Suarez et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 160 2010 346 354